CD19 and neoplasm: Moreover, we argue that CB CD19-CAR T cells could specifically recognize and kill the CD19+ ALL cell line BV173 and DLBCL cell line SUDHL-4 in an antigen-specific manner in vitro and control tumor progression in vivo.